BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10458359)

  • 1. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
    Balaji KC; Rabbani F; Tsai H; Bastar A; Fair WR
    J Urol; 1999 Sep; 162(3 Pt 1):753-7. PubMed ID: 10458359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
    Meyer F; Moore L; Bairati I; Lacombe L; Têtu B; Fradet Y
    J Urol; 1999 Dec; 162(6):2024-8. PubMed ID: 10569561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
    Lefkowitz GK; Taneja SS; Brown J; Melamed J; Lepor H
    J Urol; 2002 Oct; 168(4 Pt 1):1415-8. PubMed ID: 12352407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant high-grade prostatic intraepithelial neoplasia is associated with good prognosis factors and oncologic outcome after radical prostatectomy.
    Ingels A; Ploussard G; Allory Y; Abbou C; de la Taille A; Salomon L
    Urol Int; 2014; 92(3):264-9. PubMed ID: 23919964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of high-grade prostatic intraepithelial neoplasia for biochemical relapse of prostate carcinoma after radical prostatectomy.
    Auskalnis S; Milonas D; Jievaltas M; Vaiciūnas K; Mickevicius A; Gudinaviciene I
    Medicina (Kaunas); 2010; 46(9):604-10. PubMed ID: 21252594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
    Villavicencio Mavrich H; Chéchile Toniolo G; Salinas Duffo D; Muñoz Plaza J; Sorraca Ibáñez YJ
    Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Schulman CC; Debruyne FM; Forster G; Selvaggi FP; Zlotta AR; Witjes WP
    Eur Urol; 2000 Dec; 38(6):706-13. PubMed ID: 11111188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

  • 17. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen.
    Morote J; Raventós CX; Encabo G; López M; de Torres IM
    Eur Urol; 2000 Apr; 37(4):456-9. PubMed ID: 10765077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
    Gao X; Zhou T; Tang YJ; Lu X; Sun YH
    Asian J Androl; 2009 Jan; 11(1):127-30. PubMed ID: 19050694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy.
    van der Kwast TH; Labrie F; Tetu B
    Hum Pathol; 1999 Dec; 30(12):1503-7. PubMed ID: 10667430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.